Erlotinib and Docetaxel With Concomitant Boost Radiation Therapy (XRT) for Head and Neck Squamous Cell Carcinoma (HNSCC) - Related Studies

Erlotinib and Docetaxel With Concomitant Boost Radiation Therapy (XRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)

This study is currently recruiting participants.

Study NCT00113347. Last updated on October 29, 2008. Information provided by M.D. Anderson Cancer Center

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Head and Neck Cancer

2	Additional conditions recognized in this trial
		Carcinoma
		Carcinoma, Squamous Cell
		Head and Neck Neoplasms

3	More general conditions related to this trial
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms by Site
		Neoplasms, Glandular and Epithelial
		Neoplasms, Squamous Cell

4	Interventions listed in this trial
		Erlotinib
		Docetaxel
		Radiation Therapy

5	More general drug interventions related to this trial
		Antineoplastic Agents
		Enzyme Inhibitors
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Protein Kinase Inhibitors
		Therapeutic Uses

6	Sponsors listed in this trial
		M.D. Anderson Cancer Center
		Aventis Pharmaceuticals
		Genentech